若生智能
Drug Database
AL

albumin (Pedialb / AlbuRel / AlbuRel LS)

✓ Approved

Reliance Life Sciences Private Limited · 细胞治疗 · 细胞治疗

什么是 albumin？

albumin 是一种细胞治疗，由Reliance Life Sciences Private Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Pedialb, AlbuRel, AlbuRel LS
公司Reliance Life Sciences Private Limited
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Reliance Life Sciences Private Limited

治疗适应症

albumin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedBreast cancer (Tokyo, Japan)2026-06-13

Low protein, high risk: hypoalbuminemia predicts adverse outcomes after mastectomy in 37,848 breast cancer patients.

Schaschinger Thomas T, Niederegger Tobias T, Diatta Fortunay F, Matar Dany Y DY et al.

Hypoalbuminemia is a well-known marker of poor nutritional status and has been linked to adverse outcomes in various surgical specialties. However, its role in mastectomy remains underexplored. This study investigates the impact of hypoalbuminemia on 30-day postoperative outcomes in patients undergoing mastectomy for breast cancer. Using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2011 to 2021, we identified 37,848 female breast cancer patients who underwent mastectomy without concurrent reconstructive procedures and had documented preoperative serum albumin levels measured within 30 days of surgery. Patients were stratified by albumin level (< 3.5 g/dL vs. ≥3.5 g/dL). Multivariate logistic regression was used to assess the association between hypoalbuminemia and postoperative 30-day outcomes. ROC analysis identified albumin thresholds predictive of complications. Among 37,848 patients, 3,210 (8.5%) were hypoalbuminemic. Hypoalbuminemia was significantly associated with higher rates of any complication (16% vs. 10%; OR 1.4, p < 0.001), surgical complications (10% vs. 5.5%; OR 1.5, p < 0.001), medical complications (0.37% vs. 0.13%; OR 1.8, p < 0.001). Similarly, readmissions were significantly more frequent in hypoalbuminemic patients (7.0% vs. 3.9%; OR 1.6, p < 0.001). The need for transfusion was over three times higher (5.0% vs. 1.4%, p < 0.001), and hypoalbuminemia was associated with longer hospital stays (2.2 vs. 1.3 days, p < 0.001). Subgroup analysis revealed that these trends persisted across both total and radical mastectomy procedures. Optimal albumin thresholds for predicting complications ranged from 3.7 to 4.1 g/dL, depending on the type of complication. Preoperative hypoalbuminemia is an independent predictor of increased postoperative morbidity following mastectomy. Clinicians may consider selective albumin assessment as a pragmatic tool for identifying patients with increased physiological vulnerability who may benefit from targeted preoperative optimization strategies, rather than as a stand-alone indicator of nutritional deficiency; however, further research is needed to establish optimal testing strategies and confirm clinical benefits.

PMID 42286386
阅读全文 →
PubMedJournal of colloid and interface science2026-06-13

Reinforcement of bovine serum albumin-based interfaces by the addition of genipin and carboxymethyl cellulose: Effect of pH.

Felix Manuel M, Lendel Christofer C, Fielden Matthew M, Carrera-Sanchez Cecilio C et al.

Protein based interfacial films are a vital component of encapsulated functional food. The stability and mechanical performance of bovine serum albumin (BSA) films can be significantly enhanced through two complementary strategies: (i) electrostatic complexation for example with carboxymethyl cellulose (CMC), and (ii) interfacial covalent cross linking of BSA by genipin (GNP). Quartz crystal microbalance (QCM), interfacial small amplitude oscillatory shear rheology (iSAOS), and atomic force microscopy (AFM) were combined to quantify mass adsorption, viscoelastic film development, and interfacial morphology of BSA, both alone and in mixtures with CMC and/or GNP at pH 3.0 and 7.0. Attractive electrostatic interactions between BSA and CMC led to interfaces with the highest viscoelastic shear moduli (G' = 0.069 ± 0.004 N/m for BSA + CMC at pH 3.0). At neutral pH genepin enhanced the properties of a BSA film from predominantly liquid like to predominantly solid-like. These findings demonstrate that electrostatic complexation and interfacial cross-linking provide two complementary pathways for the reinforcement of protein-based interfacial films and reveal new routes for enhancing mechanical stability of encapsulated ingredients.

PMID 42284797
阅读全文 →
PubMedCarbohydrate polymers2026-06-13

Preparation of bovine serum albumin-γ-cyclodextrin conjugate and its solubilization and delivery performance for paclitaxel.

He Wenxin W, Song Qijun Q, Liu Qingyuan Q, Chen Xingyue X et al.

In this study, bovine serum albumin-γ-cyclodextrin (BSA-CD) conjugate was prepared to explore its solubilization effect on Paclitaxel (PTX) and the underlying mechanism. The aqueous solubility studies revealed that when 0.1 mM BSA-CD conjugate was complexed with 4 mM PTX, the maximum aqueous solubility of PTX reached 34 mM, which was approximately 5-fold higher than that of the clinical formulation Abraxane™, with drug loading capacity increased by about 2.8-fold. In vitro release studies demonstrated that the inclusion complex exhibited a cumulative PTX release of approximately 14% over 72 h at pH 7.4 and approximately 23% at pH 5.5, indicating a pH-responsive release profile. MTT assays confirmed that the BSA-CD carrier was non-cytotoxic, and the inclusion complex at the concentration of 10 μM exhibited superior cytotoxicity against melanoma B16F10 cells compared to free PTX and Abraxane™. This study confirms that the BSA-CD conjugate, through the synergistic "dual encapsulation" effect of the BSA hydrophobic pocket and the γ-CD hydrophobic cavity combined with a moderately aggregated state modulated by specific ionic strength, significantly enhances the aqueous solubility and delivery efficiency of PTX, providing a novel and efficient carrier as well as new insights for the formulation optimization of hydrophobic anticancer drugs.

PMID 42285666
阅读全文 →
PubMedBiomaterials advances2026-06-13

Quercetin loaded ZIF-8 coated human serum albumin nanoparticles relieve pulmonary fibrosis via NUAK1-YAP axis.

Chen Ke-Gong KG, Zhang Chun-Sheng CS, Ma Yu-Hang YH, Xu Han-Qing HQ et al.

Quercetin (Que) exhibits considerable therapeutic potential against pulmonary fibrosis (PF), but its clinical translation is hindered by poor aqueous solubility and low bioavailability. To address these limitations, we developed a highly biocompatible nanoplatform by encapsulating Que within ZIF-8 nanoparticles surface-modified with human serum albumin (HSA). The resulting Que@ZIF-8/HSA nanoparticles were synthesized via co-precipitation and subsequent surface modification. Comprehensive in vitro biocompatibility was verified across multiple lung cell lines. The therapeutic mechanism was investigated by analyzing M2 macrophage polarization, oxidative stress, and fibroblast activation in a macrophage-fibroblast co-culture system. The in vivo efficacy of the nanoplatform was subsequently validated in a bleomycin-induced PF mouse model using micro-CT, pulmonary function testing, and histopathological analysis. The Que@ZIF-8/HSA nanoparticles exhibited excellent colloidal stability and sustained drug release profiles with negligible systemic toxicity. Mechanistically, the nanoplatform significantly attenuated M2 macrophage polarization and mitigated oxidative damage. Notably, Que@ZIF-8/HSA-treated macrophages were found to restrict YAP nuclear translocation via NUAK1 inhibition in fibroblasts, thereby preventing the fibroblast-to-myofibroblast transition. These cellular changes translated into reduced collagen deposition and markedly improved respiratory function in vivo. Thus, Que@ZIF-8/HSA effectively disrupts the macrophage-fibroblast crosstalk through the NUAK1/YAP signaling axis, offering a potent, biocompatible microenvironment-responsive nanoplatform for Que delivery and the clinical management of PF.

PMID 42284755
阅读全文 →
PubMedWater research2026-06-13

Perfluorocarboxylic acid toxicity analysis with albumin/1-anilinonaphthalene-8-sulfonate probe assisted by machine learning.

Wu Xinda X, Ma Yicong Y, Liu Ziyao Z, Gu Cheng C

Perfluorocarboxylic acids (PFCAs) exist as mixtures in aquatic environments. However, routine PFCA monitoring remains instrument-intensive and often reports concentrations rather than mixture toxicity for water risk management. Herein, we developed a machine-learning-assisted fluorescence framework that estimates the perfluorooctanoic acid (PFOA)-equivalent toxicity (PFOAe) for aqueous PFCA mixtures. The method used a simple bovine serum albumin/1-anilinonaphthalene-8-sulfonate (BSA/ANS) probe. The machine learning framework was developed by utilizing a stacked ensemble model, including XGBoost and CatBoost base-learners with a Ridge meta-learner to decipher the nonlinear relationships between excitation emission matrices and PFOAe. On the log10(PFOAe) scale, the model achieved a root mean squared error (RMSE) of 0.286 on a held-out test set, and an RMSE of 0.280 for spiked tap-water samples. Five authentic electroplating wastewater samples further provided a limited real sample feasibility validation. The limit of detection was 0.126 µmol l-1PFOAe (52.2 µg l-1 as PFOA), enabling rapid screening and prioritization of moderately-to-highly contaminated waters rather than trace-level analysis. Moreover, the reconciliation between chemical fluorescence phenomena and data-driven mechanistic interpretation suggests that the model behavior is consistent with the underlying chemical mechanism. Our method provides a lower complexity and risk-relevant screening tool to prioritize water samples for further confirmatory instrumental analysis and support monitoring-based risk management for PFCA mixtures.

PMID 42284939
阅读全文 →
PubMedItalian journal of pediatrics2026-06-13

Predictive value of the hemoglobin-albumin-lymphocyte-platelet score for intravenous immunoglobulin resistance in children with Kawasaki disease.

Li Kai K, Li Fei F, Zeng Na N, Sang Haiyan H et al.

Intravenous immunoglobulin (IVIG) resistance is a major clinical challenge in children with Kawasaki disease (KD) and is associated with an increased risk of coronary artery lesions. Early identification of patients at high risk of IVIG resistance remains clinically important. Medical data were collected from KD patients at Anhui Provincial Hospital between January 2018 and December 2023. Multivariable logistic regression was performed to identify independent risk factors for IVIG resistance in KD. The study further performed subgroup analyses and restricted cubic spline (RCS) to visualize the dose-response association between hemoglobin-albumin-lymphocyte-platelet score (HALP) and IVIG resistance. The predictive performance of HALP was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis (DCA), and internal validation was performed using bootstrap resampling. A total of 598 patients were included, of whom 58 (9.7%) were identified as IVIG-resistant. Patients with IVIG-resistant KD had significantly lower HALP scores, and low HALP was identified as an independent risk factor for IVIG resistance. The association was consistent across subgroups defined by age, sex, and incomplete KD (IKD). The area under the curve (AUC) for HALP in predicting IVIG resistance was 0.854, outperforming NLR (AUC = 0.751), PLR (AUC = 0.793), and SII (AUC = 0.759). In addition, DCA showed that HALP provided greater net benefit when the threshold probability ranged from 0.02 to 0.63. Moreover, subgroup ROC indicated that HALP had higher predictive value in patients aged ≤ 6 months (AUC = 0.934) and ≥ 48 months (AUC = 0.947). HALP is independently associated with IVIG resistance in children with KD and demonstrated good performance for early risk stratification, particularly in patients aged ≤ 6 months and ≥ 48 months. As a simple and readily available biomarker, HALP may serve as a useful complementary tool in routine pediatric clinical practice.

PMID 42286758
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多albumin